Market Overview

Ascendiant Capital Initiates Cytori Therapeutics With Buy

Related CYTX
Benzinga's Weekly Movers For The Week Of May 25, 2018
45 Biggest Movers From Yesterday
Midday Gainers / Losers (05/24/2018) (Seeking Alpha)

Ascendiant Capital initiated coverage on Cytori Therapeutics Inc (NASDAQ: CYTX) with a Buy rating.

The target price for Cytori Therapeutics is set to $1.25.

Cytori Therapeutics shares have dropped 69.00 percent over the past 52 weeks, while the S&P 500 index has surged 10.96 percent in the same period.

Cytori Therapeutics' shares climbed 2.69 percent to $0.730 in after-hours trading.

Latest Ratings for CYTX

Mar 2018Maxim GroupMaintainsBuy
Feb 2018Laidlaw & Co.ReinstatesBuy
Jul 2017B. Riley FBRDowngradesBuyNeutral

View More Analyst Ratings for CYTX
View the Latest Analyst Ratings

Posted-In: Ascendiant CapitalInitiation Analyst Ratings


Related Articles (CYTX)

View Comments and Join the Discussion!